Evidence map›Paper›PMID 25138695›Full record

ReviewExpert opinion on drug delivery2014

Coacervate delivery systems for proteins and small molecule drugs.

Noah R Johnson, Yadong Wang

Abstract readEditorialReview
In one paragraph

Review in Expert opinion on drug delivery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Surface Engineered Biomolecular Condensates for Targeted Cell Cytotoxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Microcondensate-Mediated Intracellular Infusion of mRNA Across the Plasma Membrane.Angewandte Chemie (International ed. in English) · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Cellular Uptake of Phase-Separating Peptide Coacervates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Peptide-based coacervates in therapeutic applications.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Noah R JohnsonUniversity of Pittsburgh, Department of Bioengineering , Pittsburgh, PA 15219 , USA.
Yadong Wang

Funding

Cardiovascular Bioengineering Training ProgramT32HL076124 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SANJEEV G SHROFF · 2005 to 2026
$7.0M
Compliant and strong small arteries engineered in vitroR01HL089658 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, YADONG · 2007 to 2016
$3.4M
NHLBI NIH HHS R01 HL089658NHLBI NIH HHS T32 HL076124
6 · The paper itself

Abstract

Coacervates represent an exciting new class of drug delivery vehicles, developed in the past decade as carriers of small molecule drugs and proteins. This review summarizes several well-described coacervate systems, including: i) elastin-like peptides for delivery of anticancer therapeutics; ii) heparin-based coacervates with synthetic polycations for controlled growth factor delivery; iii) carboxymethyl chitosan aggregates for oral drug delivery; iv) Mussel adhesive protein and hyaluronic acid coacervates. Coacervates present advantages in their simple assembly and easy incorporation into tissue engineering scaffolds or as adjuncts to cell therapies. They are also amenable to functionalization such as for targeting or for enhancing the bioactivity of their cargo. These new drug carriers are anticipated to have broad applications and noteworthy impact in the near future.

Indexed as

AnimalsChitosanColloidsDrug CarriersElastinHeparinHumansProteinsadhesive protein, musselcarboxymethyl-chitosanChitosanColloidsDrug CarriersElastinHeparinProteinschitosancoacervatecontrolled releasedoxorubicindrug deliveryelastingrowth factorheparinhyaluronic acid

Identifiers

PMID25138695
PMCPMC4617778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.